Table 3.
E-mail monitoring in DRE and GLUT1–DS patients.
| DRE (N = 13) | GLUT1-DS (N = 18) | |||||
|---|---|---|---|---|---|---|
| 3 Months | 6 Months | 12 Months | 3 Months | 6 Months | 12 Months | |
| Total e-mails (n): | 11.0 (4.0–30.0) |
21.0 (11.0–38.0) |
26.0 (19.0–65.0) |
18.5 (6.0–33.0) |
24.0 (13.5–46.0) |
39.0 (25.5–56.5) |
| Dietary change requests (n): | 2.0 (2.0–4.0) |
2.0 (2.0–7.0) |
5.0 (3.0–9.0) |
3.5 (0.0–9.0) |
4.5 (1.0–16.0) |
6.0 (2.0–17.5) |
| Ketonemia (n): | 4.0 (1.0–7.0) |
5.0 (3.0–17.0) |
9.0 (6.0–25.0) |
3.5 (0.0–6.5) |
4.0 (1.0–8.0) |
5.5 (2.0–11.5) |
| Adverse effects (n): | 0.0 (0.0–1.0) |
0.0 (0.0–3.0) |
3.0 (0.0–4.0) |
0.0 (0.0–1.0) |
0.0 (0.0–1.5) |
0.0 (0.0–2.5) |
| Supplements (n): | 1.0 (0.0–2.0) |
1.0 (1.0–3.0) |
1.0 (0.0–3.0) |
0.0 (0.0–2.0) |
1.0 (0.0–3.0) |
1.5 (0.0–5.5) |
| Dietary info requests (n): | 6.0 (0.0–16.0) |
8.0 (2.0–22.0) |
8.0 (3.0–31.0) |
8.0 (1.0–13.0) |
12.5 (4.4–17.5) |
18.0 (11.0–29.5) |
| KD suspension (n): | 0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
Data are reported as medians and interquartile ranges. “Total e-mails” refers to the number of sent e-mails from epileptic (n = 13 patients) and GLUT1-DS (n = 18 patients) families at 3, 6, 12 months, respectively. There were no significant differences between 3, 6 and 12 months in each study group. Abbreviations: DRE = drug-resistant epilepsy, GLUT1-DS = glucose transporter type 1 deficiency syndrome, KD = ketogenic diet.